Hypusination-induced DHPS/eIF5A pathway as a new therapeutic strategy for human diseases: A mechanistic review and structural classification of DHPS inhibitors - 12/10/23


Abstract |
The discovery of new therapeutic strategies for diseases is essential for drug research. Deoxyhypusine synthase (DHPS) is a critical enzyme that modifies the conversion of the eukaryotic translation initiation factor 5A (eIF5A) precursor into physiologically active eIF5A (eIF5A-Hyp). Recent studies have revealed that the hypusine modifying of DHPS on eIF5A has an essential regulatory role in human diseases. The hypusination-induced DHPS/eIF5A pathway has been shown to play an essential role in various cancers, and it could regulate immune-related diseases, glucose metabolism-related diseases, neurological-related diseases, and aging. In addition, DHPS has a more defined substrate and a well-defined structure within the active pocket than eIF5A. More and more researchers are focusing on the prospect of advanced development of DHPS inhibitors. This review summarizes the regulatory mechanisms of the hypusination-induced DHPS/eIF5A pathway in a variety of diseases in addition to the inhibitors related to this pathway; it highlights and analyzes the structural features and mechanisms of action of DHPS inhibitors and expands the prospects of future drug development using DHPS as an anticancer target.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | DHPS/eIF5A could be a new strategy for cancer therapy. |
• | DHPS/eIF5A is involved in the regulatory process of diverse diseases. |
• | DHPS allosteric inhibitors have superiority over classical inhibitors. |
Abbreviations : DHPS, NAD, eIF5A, DOHH, eIF5A-Hyp, eIF5A1, eIF5A2, SPD, mRNA, Rb, DAP:1, ODC, SAM, SRM, SMS, APAO, SSAT, SMO, Rho-GTPase, MYC, TGFβ, RhoA, Rac1, HCC, OSCC, Waf1, Cip1, GB, Bcl-2, Bax, AMPK, NB, EMT, NSCLC, CRC, PEAK1, SLC3A2, CDK4/6, HERC3, Smad2/3, IGF2BP1, MMPs, GP-100, TCA cycle, H3K9, H3K4, NK cell, SREBP, TFEB, nNOS, FDA
Keywords : Deoxyhypusine synthase, Hypusine, Allosteric inhibitors
Plan
Vol 167
Article 115440- novembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
